Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Kilitch Drugs (India) Ltd Stock Analysis

Small Cap
Evaluated by 392 users | BSE: 524500 | NSE: KILITCH |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 10.19%12.18%2.92%-1.78%-0.1%-1.86%0.37%4.14%9.2%1.68%3.07%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 14610733.214.9192128.150.596.460.87084
Y-o-Y Gr. Rt.--26.8%-69%-55.1%27.7%10.5%33.9%79.3%91.1%-37%15.2%-
Adjusted EPS (Rs.) 7.9110.52.64-1.62-0.12-1.70.253.588.461.342.995.60
Y-o-Y Gr. Rt.-32.7%-74.9%-161.4%NANANA1332%136.3%-84.2%123.1%-
Book Value per Share (Rs.) 62.4186.4577.4689.8289.6388.0888.9192.8297.6697.48104.93109.48
Adjusted Net Profit 10.513.93.5-2.2-0.2-2.30.34.9132.14.69
Net Op. Cash Flow (Rs. Cr.) 25.5-29.41.5-31.1-7.6180.6-1.37.47.36.1-
Debt to Cash Flow from Ops 2.08-0.30000.011.07-0.631.261.722.4-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Kilitch Drugs (India) Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales -4.6%27.2%11.5%15.2%
Adjusted EPS -13%NA-5.8%123.1%
Book Value per Share 2.23.64.27.6
Share Price 10.2% 32.3% -4.6% 65.4%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 13.0913.872.98-1.8-0.13-1.890.283.939.211.372.955.22
Operating Profit Margin (%) 15.1613.26-11.07-25.2-5.99-14.980.4711.0717.021.937.639.57
Net Profit Margin (%) 7.171310.53-14.42-0.82-10.721.189.7513.483.416.6210.38
Debt to Equity 0.640.0800000.010.010.060.080.090
Working Capital Days 148124184632725536280193173373364302
Cash Conversion Cycle 1119382117170244163866410759177
Loading price chart...
Entity Percentage Holding
Promoters 68.33%
Non-Institutions 31.67%
Pledged *0.000.000.000.000.000.970.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Kilitch Drugs (India) Ltd's earnings have grown by 0%, whereas share price has appreciated 32.3% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Kilitch Drugs (India) Ltd share price has appreciated 10.2% annually (CAGR) over the past ten years.

Data is not available for this company.

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India.

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.

Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.

Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.

In 2010 the company listed its Equity Shares at NSE.

DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam

Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials

Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.

Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback